Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Epithalon (Injectable Form)
Epitalon Injectable, AEDG Injectable
The injectable subcutaneous form of the Epithalon tetrapeptide, offering higher bioavailability than oral or nasal routes. Same active sequence (Ala-Glu-Asp-Gly) as oral Epitalon but delivered via injection for more reliable absorption. Studied for telomerase activation, pineal gland function, and circadian rhythm regulation.
A 21-amino acid peptide encoded within the mitochondrial genome — one of the first mitochondria-derived peptides (MDPs) discovered. Humanin levels decline with age and are associated with longevity in centenarian offspring. Studied for neuroprotection, metabolic health, and cardiovascular protection.
Same mechanism as oral Epitalon — stimulates telomerase activity in somatic cells, potentially slowing telomere shortening. Also modulates pineal gland melatonin production and may influence circadian rhythm regulation. The injectable route bypasses GI degradation, providing more consistent peptide delivery to target tissues.
Binds to multiple receptors including gp130, FPRL1, and intracellular IGFBP-3. Activates STAT3 and AMPK signaling pathways. Inhibits neuronal apoptosis, reduces inflammation, improves insulin sensitivity, and protects against ischemic injury. Acts as a stress-response signal from mitochondria to the rest of the cell.
- Anti-aging and longevity protocols
- Telomere maintenance (investigational)
- Sleep quality improvement
- Circadian rhythm regulation
- Pineal gland support
- Neuroprotection and cognitive support
- Metabolic health and insulin sensitivity
- Cardiovascular protection
- Longevity and anti-aging protocols
- Alzheimer's disease research
- Injection site reactions
- Drowsiness (melatonin-related)
- Limited human clinical data
- Long-term safety unknown
- Theoretical cancer risk from telomerase activation (unproven)
- Very limited human clinical data
- Optimal dosing not established
- Long-term effects unknown
- Injection site reactions
- Interactions with other peptides not well characterized
Shares regulatory status with Epitalon. Removed from Category 2 on April 22, 2026. Scheduled for PCAC Day 2 review on July 24, 2026. Not FDA-approved for any indication.
PCAC: 2026-07-24
Not FDA-approved and not on any compounding list. Available as a research chemical. One of the more scientifically interesting longevity peptides with a growing research base, but human clinical trials are in early stages. Not affected by the 2026 regulatory changes.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.